🔴 Intellia Therapeutics is trading 5.7% down today after Anthropic’s Claude identified a CRISPR-like enzyme system

Intellia Therapeutics is trading 5.7% down at $11.63 after Anthropic’s Claude identified a previously unknown enzyme system resembling CRISPR.

• The discovery prompted declines across gene-editing stocks, though the system’s biological function and therapeutic relevance remain unproven.
• Broader weakness added pressure: biotechnology stocks were down 2.04%, while major indexes were lower amid rising Treasury yields and inflation concerns.